ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

165
Analysis
Health CareIndia
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
24 Aug 2023 09:42Broker

Top Sector Ideas - Pharma

In Q1FY24, the Pharma Coverage universe posted robust revenue growth of 20.5%/6.1% YoY/QoQ on account of volume rampup, new launches (especially...

Logo
332 Views
Share
22 Aug 2023 22:18

Zydus Lifesciences (ZYDUSLIF IN): Strong Start of FY24 Riding on US Formulation Business

Quarterly revenue surpassed INR50B mark for 2nd consecutive quarter. Even upon a high base, US revenue increased 8% sequentially driven by new...

Logo
633 Views
Share
07 Aug 2023 22:48

Sun Pharmaceutical (SUNP IN): Q1 Profit Falls Due to One-Off Expenses; Double-Digit Revenue Growth

Sun Pharma reported 11% sales growth to INR118B in Q1, driven by the US business. Net profit declined 2% to INR20B due to one-off charges....

Logo
324 Views
Share
bullishLupin Ltd
07 Aug 2023 21:27Broker

LUPIN Ltd - Positive Outlook Backed by the Launch of Niche Products

The company’s sales were up 28.6% YoY at Rs 4,330 Cr, and the growth was majorily led by its India business (+9.8% YoY), EMEA (+19.6% YoY)

Logo
272 Views
Share
03 Aug 2023 08:25Broker

Axis Top Picks - Aug 2023

The Axis Top Picks Basket returned a solid return of 10% in July’23 against the 3% return posted by Nifty 50, beating the benchmark by a wide margin.

Logo
243 Views
Share
x